NANOBIOTIX Announces First Data From Cohorts 1 And 2 Of Dose Escalation Part Of Phase 1 Study Evaluating JNJ-1900 For EADC Patients

Author: Benzinga Newsdesk | October 01, 2025 04:18pm

• Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus
• 85% (11/13) disease control rate (DCR)
• 69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responses
• Recruitment of 17 additional patients is ongoing as planned

Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st

PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced first data from cohorts 1 and 2 of the dose escalation part of a Phase 1 dose escalation and dose expansion study evaluating JNJ-1900 (NBTXR3) combined with photon chemoradiation (cohort 1) or proton chemoradiation (cohort 2) followed by surgery, if medically indicated, for patients with locally advanced adenocarcinoma of the esophagus ("EADC"). The study is sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") and results were presented by Principal Investigator Steven Lin, MD, PhD, Professor of Radiation Oncology at MD Anderson at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Posted In: NBTX